Johnson & Johnson JNJ
NYSE JNJ
$269.99 -0.22 (-0.08%)
At close: Sep 18, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Income from Discontinued Operations (2022 - 2023)

Johnson & Johnson's (JNJ) quarterly Income from Discontinued Operations came in at -$83.0 million in Q4 2023, down 128.33% year-over-year from $293.0 million in Q4 2022, and down 100.38% quarter-over-quarter from $21.7 billion in Q4 2023.

Analysis

Johnson & Johnson (JNJ) Income from Discontinued Operations (2022 - 2023) Analysis & Trends

Johnson & Johnson has disclosed Income from Discontinued Operations across 2 years of filings, most recently posting -$83.0 million for Q4 2023.

  • In Q4 2023, Income from Discontinued Operations fell 128.33% year-over-year to -$83.0 million; the TTM figure through Sep 2024 stood at -$83.0 million (down 100.37% YoY), while the FY2023 annual figure was $21.8 billion, up 1289.37% from the prior year.
  • Income from Discontinued Operations came in at -$83.0 million for Q4 2023 at Johnson & Johnson, down from $21.7 billion in the prior quarter.
  • In the past five years, Income from Discontinued Operations ranged from a high of $21.7 billion in Q4 2023 to a low of -$232.0 million in Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn -
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn -
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn 8.00 Mn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn -
8 Revolution Medicines 40.91 Bn 40.91 Bn - -
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -83.00 Mn
Oct 1, 2023 21.72 Bn
Jul 2, 2023 -232.00 Mn
Apr 2, 2023 423.00 Mn
Jan 1, 2023 293.00 Mn
Oct 2, 2022 148.00 Mn
Jul 3, 2022 552.00 Mn
Apr 3, 2022 578.00 Mn